nach oben

Zeitschrift für Rheumatologie

Erschienen in:

08.07.2021 | Rheumatoide Arthritis | Leitthema

80 Meilensteine der Rheumatologie aus 80 Jahren – III: 1980–2000

verfasst von: Prof. Dr. Gerd-Rüdiger Burmester, Joachim R. Kalden, Thomas Rose

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Auszug

Vorbemerkung: Viele der in diesem Beitrag dargestellten Meilensteine wurden von Joachim Kalden ausgesucht, der kurz nach der Fertigstellung der Liste der interessantesten Arbeiten (1980–2000) verstarb. Es war ihm leider nicht mehr vergönnt, das fertige Produkt mitzuerleben. Ihm ist dieses Kapitel, für das er den Grundstein gelegt hat, gewidmet. …

Gubner R, August S, Ginsberg V (1951) Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 221(2):176–182CrossRefPubMed

Willkens RF, Watson MA, Paxson CS (1980) Low dose pulse methotrexate therapy in rheumatoid arthritis. J Rheumatol 7(4):501–505PubMed

Williams HJ, Willkens RF, Samuelson CO Jr, Alarcón GS, Guttadauria M, Yarboro C, Polisson RP, Weiner SR, Luggen ME, Billingsley LM, Dahl SL, Egger MJ, Reading JC, Ward JR (1985) Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 28(7):721–730. https://doi.org/10.1002/art.1780280702CrossRefPubMed

Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312(13):818–822. https://doi.org/10.1056/NEJM198503283121303CrossRefPubMed

Herborn G, Rau R, Menninger H, Elhardt D, Schmitt J (1992) Zweijahresdaten der Vergleichsstudie Methotrexat/Aurothiomalat von 102 Patienten [Data of two years of the comparative study methotrexate/aurothiomalate in 102 patients. Z Rheumatol 51(4):163–171PubMed

Burmester GR, Locher P, Koch B, Winchester RJ, Dimitriu-Bona A, Kalden JR, Mohr W (1983) The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens. Rheumatol Int 3(4):173–181. https://doi.org/10.1007/BF00541597CrossRefPubMed

Müller-Ladner U, Kriegsmann J, Franklin BN et al (1996) Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149:1607–1615PubMedPubMedCentral

Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL, Zvaifler NJ (1996) Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 149:2143–2151PubMedPubMedCentral

Valencia X, Higgins JM, Kiener HP et al (2004) Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med 200(12):1673–1679CrossRefPubMedPubMedCentral

10.

Gravallese EM, Harada Y, Wang JT et al (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152(4):943–951PubMedPubMedCentral

11.

Lefèvre S, Knedla A, Tennie C et al (2009) Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 15:1414–1420CrossRefPubMedPubMedCentral

12.

Orange DE, Yao V, Sawicka K et al (2020) RNA identification of PRIME cells predicting rheumatoid arthritis flares. N Engl J Med 383:218–228CrossRefPubMedPubMedCentral

13.

Pangborn MC (1941) A new serologically active phospholipid from beef heart. Exp Biol Med (Maywood) 48:484–486. https://doi.org/10.3181/00379727-48-13365PCrossRef

14.

Harris EN, Gharavi AE, Boey ML et al (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2:1211–1214. https://doi.org/10.1016/s0140-6736(83)91267-9CrossRefPubMed

15.

Harris EN (1987) Syndrome of the black swan. Baillieres Clin Rheumatol 26:324–326. https://doi.org/10.1093/rheumatology/26.5.324CrossRef

16.

van der Woude FJ, Rasmussen N, Lobatto S et al (1985) Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1:425–429. https://doi.org/10.1016/s0140-6736(85)91147-xCrossRefPubMed

17.

Davies DJ, Moran JE, Niall JF et al (1982) Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 285:606. https://doi.org/10.1136/bmj.285.6342.606CrossRef

18.

Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11. https://doi.org/10.1002/art.37715CrossRefPubMed

19.

Gross WL, Lüdemann G, Kiefer G et al (1986) Anticytoplasmic antibodies in Wegener’s granulomatosis. Lancet 1:806. https://doi.org/10.1016/s0140-6736(86)91820-9CrossRefPubMed

20.

Falk RJ, Jennette JC (1988) Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318:1651–1657. https://doi.org/10.1056/NEJM198806233182504CrossRefPubMed

21.

Sharp JT, Bluhm GB, Brook A et al (1985) Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 28:16–24. https://doi.org/10.1002/art.1780280104CrossRefPubMed

22.

Heijde DMFMVD, Leeuwen MAV, Riel PLCMV et al (1992) Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 35:26–34. https://doi.org/10.1002/art.1780350105CrossRefPubMed

23.

Sharp JT, Lidsky MD, Collins LC et al (1971) Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 14:706–720. https://doi.org/10.1002/art.1780140605CrossRefPubMed

24.

van der Heijde D, Dankert T, Nieman F et al (1999) Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Baillieres Clin Rheumatol 38:941–947. https://doi.org/10.1093/rheumatology/38.10.941CrossRef

25.

Barnabe C, Hazlewood G, Barr S et al (2012) Comparison of radiographic scoring methods in a cohort of RA patients treated with anti-TNF therapy. Baillieres Clin Rheumatol 51:878–881. https://doi.org/10.1093/rheumatology/ker418CrossRef

26.

Lee SH, Gregersen PK, Shen HH, Nunez-Roldan A, Silver J, Winchester RJ (1984) Strong association of rheumatoid arthritis with the presence of a polymorphic Ia epitope defined by a monoclonal antibody: comparison with the allodeterminant DR4. Rheumatol Int. https://doi.org/10.1007/BF00541274CrossRefPubMed

27.

Toguchi T, Burmester G, Nunez-Roldan A, Gregersen P, Seremetis S, Lee S, Szer I, Winchester R (1984) Evidence for the separate molecular expression of four distinct polymorphic Ia epitopes on cells of DR4 homozygous individuals. Hum Immunol 10(2):69–81. https://doi.org/10.1016/0198-8859(84)90074-0CrossRefPubMed

28.

Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30(11):1205–1213. https://doi.org/10.1002/art.1780301102CrossRefPubMed

29.

Holoshitz J (2010) The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol 22(3):293–298. https://doi.org/10.1097/BOR.0b013e328336ba63CrossRefPubMedPubMedCentral

30.

Moll JM, Haslock I, Macrae IF et al (1974) Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine 53:343–364. https://doi.org/10.1097/00005792-197409000-00002CrossRefPubMed

31.

Caffrey MF, James DC (1973) Human lymphocyte antigen association in ankylosing spondylitis. Nature 242:121. https://doi.org/10.1038/242121a0CrossRefPubMed

32.

Schlosstein L, Terasaki PI, Bluestone R et al (1973) High association of an HL‑A antigen, W27, with ankylosing spondylitis. N Engl J Med 288:704–706. https://doi.org/10.1056/NEJM197304052881403CrossRefPubMed

33.

Taurog JD, Richardson JA, Croft JT et al (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364. https://doi.org/10.1084/jem.180.6.2359CrossRefPubMed

34.

Mielants H, Veys EM, Cuvelier C et al (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22:2279–2284PubMed

35.

Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150–154. https://doi.org/10.1056/NEJM199101173240303CrossRef

36.

Herzog C, Walker C, Pichler W, Aeschlimann A, Wassmer P, Stockinger H, Knapp W, Rieber P, Müller W (1987) Monoclonal anti-CD4 in arthritis. Lancet 2(8573):1461–1462. https://doi.org/10.1016/s0140-6736(87)91158-5CrossRefPubMed

37.

Horneff G, Burmester GR, Emmrich F, Kalden JR (1991) Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 34(2):129–140. https://doi.org/10.1002/art.1780340202CrossRefPubMed

38.

Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR (1993) Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL‑1, IL‑6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 91(2):207–213. https://doi.org/10.1111/j.1365-2249.1993.tb05884.xCrossRefPubMedPubMedCentral

39.

van der Lubbe PA, Reiter C, Breedveld FC, Krüger K, Schattenkirchner M, Sanders ME, Riethmüller G (1993) Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 36(10):1375–1379. https://doi.org/10.1002/art.1780361008CrossRefPubMed

40.

van der Lubbe PA, Dijkmans BA, Markusse HM, Nässander U, Breedveld FC (1995) A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38(8):1097–1106. https://doi.org/10.1002/art.1780380812CrossRefPubMed

41.

Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20(2):259–262PubMed

42.

Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin‑1 production in rheumatoid arthritis. Lancet 2(8657):244–247. https://doi.org/10.1016/s0140-6736(89)90430-3CrossRefPubMed

43.

Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36(12):1681–1690. https://doi.org/10.1002/art.1780361206CrossRefPubMed

44.

Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930):1105–1110. https://doi.org/10.1016/s0140-6736(94)90628-9CrossRefPubMed

45.

Lorenz HM, Antoni C, Valerius T, Repp R, Grünke M, Schwerdtner N, Nüsslein H, Woody J, Kalden JR, Manger B (1996) In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 156(4):1646–1653PubMed

46.

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552–1563. https://doi.org/10.1002/1529-0131(199809)41:9〈1552::AID-ART5〉3.0.CO;2‑WCrossRefPubMed

47.

Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R (1993) Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 14(4):381–394. https://doi.org/10.1007/BF00192310CrossRefPubMed

48.

Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, Campion G, Musikic P, Löw-Friedrich I, Oed C, Seifert H, Strand V (1995) Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 38(11):1595–1603. https://doi.org/10.1002/art.1780381111CrossRefPubMed

49.

Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European leflunomide study group. Lancet 353(9149):259–266. https://doi.org/10.1016/s0140-6736(98)09403-3CrossRefPubMed

50.

ter Borg EJ, Horst G, Hummel EJ et al (1990) Measurement of increases in anti-double-stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 33:634–643. https://doi.org/10.1002/art.1780330505CrossRefPubMed

51.

Ehrenstein MR, Katz DR, Griffiths MH et al (1995) Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 48:705–711. https://doi.org/10.1038/ki.1995.341CrossRefPubMed

52.

Winkler TH, Fehr H, Kalden JR (1992) Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol 22:1719–1728CrossRefPubMed

53.

Hunder GG, Bloch DA, Michel BA et al (1990) The American college of rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128. https://doi.org/10.1002/art.1780330810CrossRefPubMed

54.

Duftner C, Dejaco C, Sepriano A et al (2018) Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open 4:e612. https://doi.org/10.1136/rmdopen-2017-000612CrossRefPubMedPubMedCentral

55.

Hellmich B, Agueda A, Monti S et al (2020) 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79:19–30. https://doi.org/10.1136/annrheumdis-2019-215672CrossRefPubMed

56.

Schmidt WA, Kraft HE, Vorpahl K et al (1997) Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 337:1336–1342. https://doi.org/10.1056/NEJM199711063371902CrossRefPubMed

57.

Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337(3):141–147. https://doi.org/10.1056/NEJM199707173370301CrossRefPubMed

58.

Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med 342(11):763–769. https://doi.org/10.1056/NEJM200003163421103CrossRefPubMed

59.

Dörner T, Furie R (2019) Novel paradigms in systemic lupus erythematosus. Lancet 393:2344–2358. https://doi.org/10.1016/S0140-6736(19)30546-XCrossRefPubMed

60.

Herrmann M, Voll RE, Zoller OM et al (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41:1241–1250. https://doi.org/10.1002/1529-0131(199807)41:7〈1241::AID-ART15〉3.0.CO;2‑HCrossRefPubMed

61.

Baumann I, Kolowos W, Voll RE et al (2002) Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 46:191–201. https://doi.org/10.1002/1529-0131(200201)46:1〈191::AID-ART10027〉3.0.CO;2‑KCrossRefPubMed

62.

Voll RE, Herrmann M, Roth EA et al (1997) Immunosuppressive effects of apoptotic cells. Nature 390:350–351. https://doi.org/10.1038/37022CrossRefPubMed

63.

Bresnihan B, Alvaro-Gracia JM, Cobby M et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin‑1 receptor antagonist. Arthritis Rheum 41:2196–2204. https://doi.org/10.1002/1529-0131(199812)41:12〈2196::AID-ART15〉3.0.CO;2‑2CrossRefPubMed

64.

Klein AL, Imazio M, Cremer P et al (2021) Phase 3 trial of Interleukin‑1 trap rilonacept in recurrent pericarditis. N Engl J Med 384:31–41. https://doi.org/10.1056/NEJMoa2027892CrossRefPubMed

65.

Nienhuis RL, Mandema E (1964) A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 23(4):302–305. https://doi.org/10.1136/ard.23.4.302CrossRefPubMedPubMedCentral

66.

Young BJJ, Mallya RK, Leslie RDJ, Clark CJM, Hamblin TJ (1979) Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2:97–99CrossRefPubMedPubMedCentral

67.

Hoet RM, Boerbooms AMT, Arends M, Ruiter DJ, van Venrooij WJ (1991) Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis 50:611–618CrossRefPubMedPubMedCentral

68.

Simon M, Girbal E, Sebbag M, Gomés-Daudrix V, Vincent C, Salema G, Serre G (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called „antikeratin antibodies,“ autoantibodies specific for rheumatoid arthritis. J Clin Invest 92:1387–1393CrossRefPubMedPubMedCentral

69.

Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, Serre G (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:2672–2679CrossRefPubMedPubMedCentral

70.

Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101(1):273–281. https://doi.org/10.1172/JCI1316CrossRefPubMedPubMedCentral

71.

Kempeni J (1999) Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis 58(1):I70–2. https://doi.org/10.1136/ard.58.2008.i70CrossRefPubMedPubMedCentral

72.

Rau R (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61(2):ii70–3. https://doi.org/10.1136/ard.61.suppl_2.ii70CrossRefPubMedPubMedCentral

73.

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45. https://doi.org/10.1002/art.10697CrossRefPubMed

74.

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26–37. https://doi.org/10.1002/art.21519CrossRefPubMed

75.

Manger B, Kalden JR (1995) Joint and connective tissue ultrasonography—a rheumatologic bedside procedure? A German experience. Arthritis Rheum 38:736–742. https://doi.org/10.1002/art.1780380603CrossRefPubMed

76.

Backhaus M, Kamradt T, Sandrock D et al (1999) Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum 42:1232–1245. https://doi.org/10.1002/1529-0131(199906)42:6〈1232::AID-ANR21〉3.0.CO;2‑3CrossRefPubMed

77.

Tyndall A, Fassas A, Passweg J et al (1999) Autologous haematopoietic stem cell transplants for autoimmune disease—feasibility and transplant-related mortality. Autoimmune disease and lymphoma working parties of the European group for blood and marrow transplantation, the European league against rheumatism and the international stem cell project for autoimmune disease. Bone Marrow Transplant 24:729–734. https://doi.org/10.1038/sj.bmt.1701987CrossRefPubMed

78.

Rosen O, Thiel A, Massenkeil G et al (2000) Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res 2:327–336. https://doi.org/10.1186/ar107CrossRefPubMedPubMedCentral

79.

Alexander T, Thiel A, Rosen O et al (2009) Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113:214–223CrossRefPubMed

80.

Snowden JA, Badoglio M, Labopin M et al (2017) Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv 1:2742–2755. https://doi.org/10.1182/bloodadvances.2017010041CrossRefPubMedPubMedCentral

Titel: 80 Meilensteine der Rheumatologie aus 80 Jahren – III: 1980–2000
verfasst von: Prof. Dr. Gerd-Rüdiger Burmester
Joachim R. Kalden
Thomas Rose
Publikationsdatum: 08.07.2021
Verlag: Springer Medizin
Schlagwort: Rheumatoide Arthritis
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 6/2021
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-021-01037-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

80 Meilensteine der Rheumatologie aus 80 Jahren – II: 1961–1980

Mitteilungen der DGRh - Veranstaltungen der Rheumaakademie

Post-COVID‑19-Arthritis. Manifestation unter dem klinischen Bild einer reaktiven Arthritis

Mitteilungen der DRL

Kombinierte MRT/MRA für die Diagnostik der RZA